Nectero Medical
Dover, US · Founded 2017 · 2 known investors
Nectero Therapeutics develops an endovascular treatment system (Nectero EAST) designed to stabilize small to mid-sized abdominal aortic aneurysms and prevent rupture, targeting patients who currently lack treatment options below the surgical intervention threshold. The company is a clinical-stage biotech firm focused on novel therapies for aneurysmal disease.
BiotechHealthtechMedical Devices
Founders & leadership
JS
John SpringerExecutive Officer, Director
BR
Bruce RobertsDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$32.8MraisedMay 2024 · 30 investors · BiotechnologyRule 506(b)
▶$32.8MraisedMay 2024 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anil DasuDirector
- Colin MorrisonDirector
- Bryan ZieglerExecutive Officer
- Bruce RobertsDirector
- Jack SpringerExecutive Officer, Director
- Robert WhirleyDirector
- Offering amount
- $96.6M
- Amount sold
- $32.8M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedSep 2021 · 31 investors · BiotechnologyRule 506(b)
▶$18.2MraisedSep 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpringerExecutive Officer, Director
- Offering amount
- $18.2M
- Amount sold
- $18.2M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.5MofferedApr 2020 · BiotechnologyRule 506(b)
▶$1.5MofferedApr 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpringerExecutive Officer, Director
- Bruce RobertsDirector
- Offering amount
- $1.5M
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.